FDAnews
www.fdanews.com/articles/123021-glaxosmithkline-boosts-arthritis-drugs-deal-with-galapagos-to-291-million

GlaxoSmithKline Boosts Arthritis-Drugs Deal With Galapagos to $291 Million

December 16, 2009
GlaxoSmithKline, the U.K.-based pharma giant with North American headquarters in Research Triangle Park, has extended its agreement with Belgian-drug maker Galapagos to develop new arthritis drugs.
Triangle Business Journal